Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.

PLoS Pathog · 2018 · PMC6107261 · PMID 30138408

Europe PMC DOI

hedged sentence

0.0644

closest p · 1.3× alpha

0.0644

boldest claim

The sentences

did not reach statistical significancep = 0.0644so close (0.05 < p ≤ 0.1)

The in vivo activity of the antibody was similar to that of another glycan cap-specific mAb BDBV289 with 80% protection (4 out of 5 mice), with similar dynamics of changes in weight and disease score, although the difference in animal survival between BDBV270 and 2D22 mAb groups did not reach statistical significance (p = 0.0644, Mantel-Cox test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.